Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
116.995USD
+7.675+7.02%
Market hours （ET）Quotes delayed by 15 min
9.61BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-29The current earnings forecast score of Kymera Therapeutics Inc is 8.67, ranking 70 out of 387 in the Biotechnology & Medical Research industry. The average price target is 90.50, with a high of 138.00 and a low of 65.00.
Analyst Rating
Based on
23
analysts
Buy
Current Rating
123.200
Target Price
+13.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kymera Therapeutics Inc
KYMR
23
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Kymera Therapeutics Inc's expected revenue for the next quarter?
Kymera Therapeutics Inc's expected revenue is 29.38M.
What is Kymera Therapeutics Inc's price target?
Analysts forecast that Kymera Therapeutics Inc's price target is USD 90.50, with the highest forecast at USD 138.00 and the lowest forecast at USD 65.00.
How have Kymera Therapeutics IncKYMR's recent earnings per share performed?
The market expectation was USD -0.71, while Kymera Therapeutics IncKYMR's earnings per share (EPS) for the previous quarter was USD -0.97. EPS for the next quarter is expected at USD -0.73.
What is the analyst rating for Kymera Therapeutics Inc?
Based on the ratings of Kymera Therapeutics Inc's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
